习惯了__就好的个人主页 - 老虎社区

习惯了__就好

习惯了__就好

暂无个人介绍

IP属地：贵州

10关注

0粉丝

1主题

0勋章

习惯了__就好

01-05

$东阳光药(06887)$ **中的**

习惯了__就好

02-25

$东阳光药(06887)$ 拿什么来拯救你[害羞] [害羞] [害羞]

习惯了__就好

02-04

$东阳光药(06887)$ 无法无天了

习惯了__就好

01-26

明天大涨

东阳光药(06887)与深圳晶泰订立战略合作协议，拟成立合资公司，共建AI驱动药物研发平台

习惯了__就好

01-05

明天大涨

东阳光药(06887)：HECN30227已完成国内首例受试者入组

习惯了__就好

2025-09-23

200手中一签

习惯了__就好

2025-08-21

$东阳光药(06887)$ 狗托些出来走两圈

习惯了__就好

2025-07-23

75

习惯了__就好

2025-04-17

哈哈哈

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4090276866863740","uuid":"4090276866863740","gmtCreate":1627173802680,"gmtModify":1627179540004,"name":"习惯了__就好","pinyin":"xgljhxiguanlejiuhao","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/4fa880c152bfa6f9ab5710f93198d571","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":10,"tweetSize":9,"questionSize":0,"limitLevel":999,"accountStatus":3,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.09.03","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.07.04","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.04.26","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"wearingSort":0}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":"贵州","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":3,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":536432407409344,"gmtCreate":1771985828365,"gmtModify":1771985830740,"author":{"id":"4090276866863740","authorId":"4090276866863740","name":"习惯了__就好","avatar":"https://static.tigerbbs.com/4fa880c152bfa6f9ab5710f93198d571","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4090276866863740","idStr":"4090276866863740"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/06887\">$东阳光药(06887)$ </a> 拿什么来拯救你[害羞]&nbsp;&nbsp;[害羞]&nbsp;&nbsp;[害羞]&nbsp;&nbsp;","listText":"<a href=\"https://laohu8.com/S/06887\">$东阳光药(06887)$ </a> 拿什么来拯救你[害羞]&nbsp;&nbsp;[害羞]&nbsp;&nbsp;[害羞]&nbsp;&nbsp;","text":"$东阳光药(06887)$ 拿什么来拯救你[害羞] [害羞] [害羞]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/536432407409344","isVote":1,"tweetType":1,"viewCount":640,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":529166457933832,"gmtCreate":1770180967420,"gmtModify":1770180969211,"author":{"id":"4090276866863740","authorId":"4090276866863740","name":"习惯了__就好","avatar":"https://static.tigerbbs.com/4fa880c152bfa6f9ab5710f93198d571","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4090276866863740","idStr":"4090276866863740"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/06887\">$东阳光药(06887)$ </a> 无法无天了","listText":"<a href=\"https://laohu8.com/S/06887\">$东阳光药(06887)$ </a> 无法无天了","text":"$东阳光药(06887)$ 无法无天了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/529166457933832","isVote":1,"tweetType":1,"viewCount":709,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":525941483864336,"gmtCreate":1769428556312,"gmtModify":1769428559034,"author":{"id":"4090276866863740","authorId":"4090276866863740","name":"习惯了__就好","avatar":"https://static.tigerbbs.com/4fa880c152bfa6f9ab5710f93198d571","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4090276866863740","idStr":"4090276866863740"},"themes":[],"title":"","htmlText":"明天大涨","listText":"明天大涨","text":"明天大涨","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/525941483864336","repostId":"2606214314","repostType":2,"repost":{"id":"2606214314","kind":"news","pubTimestamp":1769425884,"share":"https://www.laohu8.com/m/news/2606214314?lang=zh_CN&edition=full","pubTime":"2026-01-26 19:11","market":"fut","language":"zh","title":"东阳光药(06887)与深圳晶泰订立战略合作协议，拟成立合资公司，共建AI驱动药物研发平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2606214314","media":"智通财经","summary":"智通财经APP讯，东阳光药 发布公告，本公司于2026年1月26日与深圳晶泰科技有限公司订立战略合作协议。大模型联合开发及推广基于本公司多靶点的高质量非临床数据，与深圳晶泰的AI算法平台与大模型训练能力结合，开发对标行业前沿主流商业软件的PB-PK预测大模型，并共建覆盖药物研发全生命周期的AI药物研发引擎。因此，董事会认为，签订战略合作协议符合本公司及其股东的整体利益。","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/06887\">东阳光药</a>(06887)发布公告，本公司于2026年1月26日与深圳<a href=\"https://laohu8.com/S/02228\">晶泰</a>科技有限公司(深圳晶泰)订立战略合作协议(战略合作协议)。根据战略合作协议，双方拟成立合资公司，共建AI驱动药物研发平台，聚焦以下合作：</p><p><strong>(1)成立联合实验室，联合开发创新药物管线</strong></p><p>双方共建联合实验室，以AI驱动的自动化为目标，依托深圳晶泰自动化实验平台技术和部署经验，实现“设计—构建—测试—学习”研发闭环，聚焦自身免疫性疾病，共同发现候选药物并由合资公司推进。</p><p><strong>(2)大模型联合开发及推广</strong></p><p>基于本公司多靶点的高质量非临床数据，与深圳晶泰的AI算法平台与大模型训练能力结合，开发对标行业前沿主流商业软件的PB-PK预测大模型，并共建覆盖药物研发全生命周期的AI药物研发引擎。</p><p>依托深圳晶泰全球化的商业网络和AI平台产品化经验，推广本集团自主开发的“HEC-SynAI药物合成大模型”和“HEC-PharmAI制剂大模型”，以及全新一代PB-PK大模型。</p><p><strong>(3)创建“模型即服务”(MaaS)的商业模式</strong></p><p>双方计划以“算力支撑+数据开发+生态共享”模式共建AI超算平台，向学界与业界开放合作成果，将数据资产和AI产品转化为“模型即服务”(MaaS)的商业模式。</p><p>董事会认为，战略合作协议为订约方提供宝贵机会利用各自的资源及专业知识，为彼此创造互利及协同效应。因此，董事会认为，签订战略合作协议符合本公司及其股东的整体利益。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>东阳光药(06887)与深圳晶泰订立战略合作协议，拟成立合资公司，共建AI驱动药物研发平台</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n东阳光药(06887)与深圳晶泰订立战略合作协议，拟成立合资公司，共建AI驱动药物研发平台\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-26 19:11 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1397459.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，东阳光药(06887)发布公告，本公司于2026年1月26日与深圳晶泰科技有限公司(深圳晶泰)订立战略合作协议(战略合作协议)。根据战略合作协议，双方拟成立合资公司，共建AI驱动药物研发平台，聚焦以下合作：(1)成立联合实验室，联合开发创新药物管线双方共建联合实验室，以AI驱动的自动化为目标，依托深圳晶泰自动化实验平台技术和部署经验，实现“设计—构建—测试—学习”研发闭环，聚焦...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1397459.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1191":"制药","06887":"东阳光药"},"source_url":"http://www.zhitongcaijing.com/content/detail/1397459.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2606214314","content_text":"智通财经APP讯，东阳光药(06887)发布公告，本公司于2026年1月26日与深圳晶泰科技有限公司(深圳晶泰)订立战略合作协议(战略合作协议)。根据战略合作协议，双方拟成立合资公司，共建AI驱动药物研发平台，聚焦以下合作：(1)成立联合实验室，联合开发创新药物管线双方共建联合实验室，以AI驱动的自动化为目标，依托深圳晶泰自动化实验平台技术和部署经验，实现“设计—构建—测试—学习”研发闭环，聚焦自身免疫性疾病，共同发现候选药物并由合资公司推进。(2)大模型联合开发及推广基于本公司多靶点的高质量非临床数据，与深圳晶泰的AI算法平台与大模型训练能力结合，开发对标行业前沿主流商业软件的PB-PK预测大模型，并共建覆盖药物研发全生命周期的AI药物研发引擎。依托深圳晶泰全球化的商业网络和AI平台产品化经验，推广本集团自主开发的“HEC-SynAI药物合成大模型”和“HEC-PharmAI制剂大模型”，以及全新一代PB-PK大模型。(3)创建“模型即服务”(MaaS)的商业模式双方计划以“算力支撑+数据开发+生态共享”模式共建AI超算平台，向学界与业界开放合作成果，将数据资产和AI产品转化为“模型即服务”(MaaS)的商业模式。董事会认为，战略合作协议为订约方提供宝贵机会利用各自的资源及专业知识，为彼此创造互利及协同效应。因此，董事会认为，签订战略合作协议符合本公司及其股东的整体利益。","news_type":1,"symbols_score_info":{"06887":1.5}},"isVote":1,"tweetType":1,"viewCount":554,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":518493925307488,"gmtCreate":1767614720724,"gmtModify":1767614722918,"author":{"id":"4090276866863740","authorId":"4090276866863740","name":"习惯了__就好","avatar":"https://static.tigerbbs.com/4fa880c152bfa6f9ab5710f93198d571","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4090276866863740","idStr":"4090276866863740"},"themes":[],"title":"","htmlText":"明天大涨","listText":"明天大涨","text":"明天大涨","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/518493925307488","repostId":"2601835998","repostType":2,"repost":{"id":"2601835998","kind":"news","pubTimestamp":1767611765,"share":"https://www.laohu8.com/m/news/2601835998?lang=zh_CN&edition=full","pubTime":"2026-01-05 19:16","market":"hk","language":"zh","title":"东阳光药(06887)：HECN30227已完成国内首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2601835998","media":"智通财经","summary":"智通财经APP讯，东阳光药 发布公告，HECN30227是集团自主研发并拥有全球知识产权的1类新药，可同时消除 cccDNA和intDNA来源的乙肝表面抗原。临床前数据表明，HECN30227具有泛基因型活性，可高效降低HBsAg水平，对核苷类药物耐药株同样保持突出药效，体内外药效亦优于临床竞品。截至目前，HECN30227已完成国内首例受试者入组。临床前重点品种包括：乙肝ASO：除了HECN30227，公司正同步开发“siRNA+ASO+免疫调节剂”三联疗法，通过多靶点协同作用全面抑制HBV和HBsAg。","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/06887\">东阳光药</a>(06887)发布公告，HECN30227是集团自主研发并拥有全球知识产权的1类新药，可同时消除 cccDNA和intDNA来源的乙肝表面抗原(HBsAg)。临床前数据表明，HECN30227具有泛基因型活性，可高效降低HBsAg水平，对核苷类药物耐药株同样保持突出药效，体内外药效亦优于临床竞品。HECN30227采用集团独特设计的HEC GalNova(N-乙酰半乳糖胺)肝靶向递送系统，在实现精准高效肝脏递送的同时大幅降低脱靶风险。截至目前，HECN30227已完成国内首例受试者入组。</p><p>HECN30227与公司自研的免疫调节剂HEC191834临床前联合用药的重要研究成果，入选2025年美国肝脏疾病研究学会年会(AASLD)“Poster of Distinction”，该称号仅授予评分位列前10%的成果，标志着国际权威学术机构对HECN30227联用组合临床开发潜力的高度认可。</p><p>集团自2022年起进军小核酸领域，构建了“靶点发现-序列设计与合成-化学修饰-递送技术-生物学评价”的全链条研发平台，研发实力已跃居国内第一梯队。依托这一完善的技术平台，公司已申请专利超过50篇，布局超10款小核酸管线，涵盖抗感染、心血管-肾脏-代谢、呼吸系统与肿瘤四大领域，计划未来将保持每年推动多款小核酸药物进入临床阶段，持续巩固自身在小核酸治疗领域的技术领先优势。</p><p>临床前重点品种包括：乙肝ASO：除了HECN30227，公司正同步开发“siRNA+ASO+免疫调节剂”三联疗法，通过多靶点协同作用全面抑制HBV和HBsAg。其中HEC ASO与竞品相比临床前体内外药效更优。双靶点系列：通过“一药双靶”设计，同时沉默两个致病基因或同一基因的多个区域，为复杂疾病提供联合干预的高效解决方案，针对高血脂、高血脂高血压的系列双靶点管线，目前多个分子在大动物模型上显示出强效持久的活性。此外，针对MASH等适应症的双靶点管线正稳步推进中，未来将陆续推进至临床阶段。 脂肪靶向、肺部靶向、抗体递送(AOC)：针对脂肪组织高表达的ALK7靶点，公司自主设计的递送载体在小鼠的脂肪组织对ALK7敲降活性显著于阳性对照，且多个ALK7体外序列活性优于阳性对照。此外，用于治疗肺纤维化的双靶点管线(肺部靶向)、用于治疗癌症的AOC管线正稳步推进中，未来将陆续推进至临床阶段。</p><p>从乙肝siRNA疗法HECN30227开展I期临床到双靶点、脂肪靶向、肺部靶向、AOC 等丰富布局，集团正以“技术+管线+产业化”的立体化布局引领中国小核酸药物创新浪潮。未来，集团将持续加码小核酸技术平台建设，加速攻克未满足的临床需求，为患者带来全球领先的“中国智造”治疗方案。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>东阳光药(06887)：HECN30227已完成国内首例受试者入组</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n东阳光药(06887)：HECN30227已完成国内首例受试者入组\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-05 19:16 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1388791.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，东阳光药(06887)发布公告，HECN30227是集团自主研发并拥有全球知识产权的1类新药，可同时消除 cccDNA和intDNA来源的乙肝表面抗原(HBsAg)。临床前数据表明，HECN30227具有泛基因型活性，可高效降低HBsAg水平，对核苷类药物耐药株同样保持突出药效，体内外药效亦优于临床竞品。HECN30227采用集团独特设计的HEC GalNova(N-乙酰半乳糖胺...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1388791.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1191":"制药","06887":"东阳光药"},"source_url":"http://www.zhitongcaijing.com/content/detail/1388791.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2601835998","content_text":"智通财经APP讯，东阳光药(06887)发布公告，HECN30227是集团自主研发并拥有全球知识产权的1类新药，可同时消除 cccDNA和intDNA来源的乙肝表面抗原(HBsAg)。临床前数据表明，HECN30227具有泛基因型活性，可高效降低HBsAg水平，对核苷类药物耐药株同样保持突出药效，体内外药效亦优于临床竞品。HECN30227采用集团独特设计的HEC GalNova(N-乙酰半乳糖胺)肝靶向递送系统，在实现精准高效肝脏递送的同时大幅降低脱靶风险。截至目前，HECN30227已完成国内首例受试者入组。HECN30227与公司自研的免疫调节剂HEC191834临床前联合用药的重要研究成果，入选2025年美国肝脏疾病研究学会年会(AASLD)“Poster of Distinction”，该称号仅授予评分位列前10%的成果，标志着国际权威学术机构对HECN30227联用组合临床开发潜力的高度认可。集团自2022年起进军小核酸领域，构建了“靶点发现-序列设计与合成-化学修饰-递送技术-生物学评价”的全链条研发平台，研发实力已跃居国内第一梯队。依托这一完善的技术平台，公司已申请专利超过50篇，布局超10款小核酸管线，涵盖抗感染、心血管-肾脏-代谢、呼吸系统与肿瘤四大领域，计划未来将保持每年推动多款小核酸药物进入临床阶段，持续巩固自身在小核酸治疗领域的技术领先优势。临床前重点品种包括：乙肝ASO：除了HECN30227，公司正同步开发“siRNA+ASO+免疫调节剂”三联疗法，通过多靶点协同作用全面抑制HBV和HBsAg。其中HEC ASO与竞品相比临床前体内外药效更优。双靶点系列：通过“一药双靶”设计，同时沉默两个致病基因或同一基因的多个区域，为复杂疾病提供联合干预的高效解决方案，针对高血脂、高血脂高血压的系列双靶点管线，目前多个分子在大动物模型上显示出强效持久的活性。此外，针对MASH等适应症的双靶点管线正稳步推进中，未来将陆续推进至临床阶段。 脂肪靶向、肺部靶向、抗体递送(AOC)：针对脂肪组织高表达的ALK7靶点，公司自主设计的递送载体在小鼠的脂肪组织对ALK7敲降活性显著于阳性对照，且多个ALK7体外序列活性优于阳性对照。此外，用于治疗肺纤维化的双靶点管线(肺部靶向)、用于治疗癌症的AOC管线正稳步推进中，未来将陆续推进至临床阶段。从乙肝siRNA疗法HECN30227开展I期临床到双靶点、脂肪靶向、肺部靶向、AOC 等丰富布局，集团正以“技术+管线+产业化”的立体化布局引领中国小核酸药物创新浪潮。未来，集团将持续加码小核酸技术平台建设，加速攻克未满足的临床需求，为患者带来全球领先的“中国智造”治疗方案。","news_type":1,"symbols_score_info":{"06887":1.5}},"isVote":1,"tweetType":1,"viewCount":585,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":518359665623640,"gmtCreate":1767581858103,"gmtModify":1767581860076,"author":{"id":"4090276866863740","authorId":"4090276866863740","name":"习惯了__就好","avatar":"https://static.tigerbbs.com/4fa880c152bfa6f9ab5710f93198d571","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4090276866863740","idStr":"4090276866863740"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/06887\">$东阳光药(06887)$ </a> **中的**","listText":"<a href=\"https://laohu8.com/S/06887\">$东阳光药(06887)$ </a> **中的**","text":"$东阳光药(06887)$ **中的**","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/518359665623640","isVote":1,"tweetType":1,"viewCount":1563,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":481753468425088,"gmtCreate":1758639596512,"gmtModify":1758640713515,"author":{"id":"4090276866863740","authorId":"4090276866863740","name":"习惯了__就好","avatar":"https://static.tigerbbs.com/4fa880c152bfa6f9ab5710f93198d571","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4090276866863740","idStr":"4090276866863740"},"themes":[],"title":"","htmlText":"200手中一签","listText":"200手中一签","text":"200手中一签","images":[{"img":"https://static.tigerbbs.com/0f475a1bea19f70cd05f78495f251436","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/481753468425088","isVote":1,"tweetType":1,"viewCount":481,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":470180818288696,"gmtCreate":1755761609110,"gmtModify":1755763590848,"author":{"id":"4090276866863740","authorId":"4090276866863740","name":"习惯了__就好","avatar":"https://static.tigerbbs.com/4fa880c152bfa6f9ab5710f93198d571","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4090276866863740","idStr":"4090276866863740"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/06887\">$东阳光药(06887)$ </a> 狗托些出来走两圈","listText":"<a href=\"https://laohu8.com/S/06887\">$东阳光药(06887)$ </a> 狗托些出来走两圈","text":"$东阳光药(06887)$ 狗托些出来走两圈","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/470180818288696","isVote":1,"tweetType":1,"viewCount":1112,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":459603190625120,"gmtCreate":1753245118680,"gmtModify":1753246158375,"author":{"id":"4090276866863740","authorId":"4090276866863740","name":"习惯了__就好","avatar":"https://static.tigerbbs.com/4fa880c152bfa6f9ab5710f93198d571","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4090276866863740","idStr":"4090276866863740"},"themes":[],"title":"","htmlText":"75","listText":"75","text":"75","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/459603190625120","isVote":1,"tweetType":1,"viewCount":887,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":425544846680264,"gmtCreate":1744902897154,"gmtModify":1744902915823,"author":{"id":"4090276866863740","authorId":"4090276866863740","name":"习惯了__就好","avatar":"https://static.tigerbbs.com/4fa880c152bfa6f9ab5710f93198d571","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4090276866863740","idStr":"4090276866863740"},"themes":[],"title":"","htmlText":"哈哈哈","listText":"哈哈哈","text":"哈哈哈","images":[{"img":"https://static.tigerbbs.com/86d727a6fb9b2187825f4d96106f94fa","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/425544846680264","isVote":1,"tweetType":1,"viewCount":1164,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0}],"hots":[{"id":518359665623640,"gmtCreate":1767581858103,"gmtModify":1767581860076,"author":{"id":"4090276866863740","authorId":"4090276866863740","name":"习惯了__就好","avatar":"https://static.tigerbbs.com/4fa880c152bfa6f9ab5710f93198d571","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4090276866863740","authorIdStr":"4090276866863740"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/06887\">$东阳光药(06887)$ </a> **中的**","listText":"<a href=\"https://laohu8.com/S/06887\">$东阳光药(06887)$ </a> **中的**","text":"$东阳光药(06887)$ **中的**","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/518359665623640","isVote":1,"tweetType":1,"viewCount":1563,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":536432407409344,"gmtCreate":1771985828365,"gmtModify":1771985830740,"author":{"id":"4090276866863740","authorId":"4090276866863740","name":"习惯了__就好","avatar":"https://static.tigerbbs.com/4fa880c152bfa6f9ab5710f93198d571","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4090276866863740","authorIdStr":"4090276866863740"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/06887\">$东阳光药(06887)$ </a> 拿什么来拯救你[害羞]&nbsp;&nbsp;[害羞]&nbsp;&nbsp;[害羞]&nbsp;&nbsp;","listText":"<a href=\"https://laohu8.com/S/06887\">$东阳光药(06887)$ </a> 拿什么来拯救你[害羞]&nbsp;&nbsp;[害羞]&nbsp;&nbsp;[害羞]&nbsp;&nbsp;","text":"$东阳光药(06887)$ 拿什么来拯救你[害羞] [害羞] [害羞]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/536432407409344","isVote":1,"tweetType":1,"viewCount":640,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":529166457933832,"gmtCreate":1770180967420,"gmtModify":1770180969211,"author":{"id":"4090276866863740","authorId":"4090276866863740","name":"习惯了__就好","avatar":"https://static.tigerbbs.com/4fa880c152bfa6f9ab5710f93198d571","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4090276866863740","authorIdStr":"4090276866863740"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/06887\">$东阳光药(06887)$ </a> 无法无天了","listText":"<a href=\"https://laohu8.com/S/06887\">$东阳光药(06887)$ </a> 无法无天了","text":"$东阳光药(06887)$ 无法无天了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/529166457933832","isVote":1,"tweetType":1,"viewCount":709,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":525941483864336,"gmtCreate":1769428556312,"gmtModify":1769428559034,"author":{"id":"4090276866863740","authorId":"4090276866863740","name":"习惯了__就好","avatar":"https://static.tigerbbs.com/4fa880c152bfa6f9ab5710f93198d571","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4090276866863740","authorIdStr":"4090276866863740"},"themes":[],"title":"","htmlText":"明天大涨","listText":"明天大涨","text":"明天大涨","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/525941483864336","repostId":"2606214314","repostType":2,"repost":{"id":"2606214314","kind":"news","pubTimestamp":1769425884,"share":"https://www.laohu8.com/m/news/2606214314?lang=zh_CN&edition=full","pubTime":"2026-01-26 19:11","market":"fut","language":"zh","title":"东阳光药(06887)与深圳晶泰订立战略合作协议，拟成立合资公司，共建AI驱动药物研发平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2606214314","media":"智通财经","summary":"智通财经APP讯，东阳光药 发布公告，本公司于2026年1月26日与深圳晶泰科技有限公司订立战略合作协议。大模型联合开发及推广基于本公司多靶点的高质量非临床数据，与深圳晶泰的AI算法平台与大模型训练能力结合，开发对标行业前沿主流商业软件的PB-PK预测大模型，并共建覆盖药物研发全生命周期的AI药物研发引擎。因此，董事会认为，签订战略合作协议符合本公司及其股东的整体利益。","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/06887\">东阳光药</a>(06887)发布公告，本公司于2026年1月26日与深圳<a href=\"https://laohu8.com/S/02228\">晶泰</a>科技有限公司(深圳晶泰)订立战略合作协议(战略合作协议)。根据战略合作协议，双方拟成立合资公司，共建AI驱动药物研发平台，聚焦以下合作：</p><p><strong>(1)成立联合实验室，联合开发创新药物管线</strong></p><p>双方共建联合实验室，以AI驱动的自动化为目标，依托深圳晶泰自动化实验平台技术和部署经验，实现“设计—构建—测试—学习”研发闭环，聚焦自身免疫性疾病，共同发现候选药物并由合资公司推进。</p><p><strong>(2)大模型联合开发及推广</strong></p><p>基于本公司多靶点的高质量非临床数据，与深圳晶泰的AI算法平台与大模型训练能力结合，开发对标行业前沿主流商业软件的PB-PK预测大模型，并共建覆盖药物研发全生命周期的AI药物研发引擎。</p><p>依托深圳晶泰全球化的商业网络和AI平台产品化经验，推广本集团自主开发的“HEC-SynAI药物合成大模型”和“HEC-PharmAI制剂大模型”，以及全新一代PB-PK大模型。</p><p><strong>(3)创建“模型即服务”(MaaS)的商业模式</strong></p><p>双方计划以“算力支撑+数据开发+生态共享”模式共建AI超算平台，向学界与业界开放合作成果，将数据资产和AI产品转化为“模型即服务”(MaaS)的商业模式。</p><p>董事会认为，战略合作协议为订约方提供宝贵机会利用各自的资源及专业知识，为彼此创造互利及协同效应。因此，董事会认为，签订战略合作协议符合本公司及其股东的整体利益。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>东阳光药(06887)与深圳晶泰订立战略合作协议，拟成立合资公司，共建AI驱动药物研发平台</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n东阳光药(06887)与深圳晶泰订立战略合作协议，拟成立合资公司，共建AI驱动药物研发平台\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-26 19:11 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1397459.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，东阳光药(06887)发布公告，本公司于2026年1月26日与深圳晶泰科技有限公司(深圳晶泰)订立战略合作协议(战略合作协议)。根据战略合作协议，双方拟成立合资公司，共建AI驱动药物研发平台，聚焦以下合作：(1)成立联合实验室，联合开发创新药物管线双方共建联合实验室，以AI驱动的自动化为目标，依托深圳晶泰自动化实验平台技术和部署经验，实现“设计—构建—测试—学习”研发闭环，聚焦...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1397459.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1191":"制药","06887":"东阳光药"},"source_url":"http://www.zhitongcaijing.com/content/detail/1397459.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2606214314","content_text":"智通财经APP讯，东阳光药(06887)发布公告，本公司于2026年1月26日与深圳晶泰科技有限公司(深圳晶泰)订立战略合作协议(战略合作协议)。根据战略合作协议，双方拟成立合资公司，共建AI驱动药物研发平台，聚焦以下合作：(1)成立联合实验室，联合开发创新药物管线双方共建联合实验室，以AI驱动的自动化为目标，依托深圳晶泰自动化实验平台技术和部署经验，实现“设计—构建—测试—学习”研发闭环，聚焦自身免疫性疾病，共同发现候选药物并由合资公司推进。(2)大模型联合开发及推广基于本公司多靶点的高质量非临床数据，与深圳晶泰的AI算法平台与大模型训练能力结合，开发对标行业前沿主流商业软件的PB-PK预测大模型，并共建覆盖药物研发全生命周期的AI药物研发引擎。依托深圳晶泰全球化的商业网络和AI平台产品化经验，推广本集团自主开发的“HEC-SynAI药物合成大模型”和“HEC-PharmAI制剂大模型”，以及全新一代PB-PK大模型。(3)创建“模型即服务”(MaaS)的商业模式双方计划以“算力支撑+数据开发+生态共享”模式共建AI超算平台，向学界与业界开放合作成果，将数据资产和AI产品转化为“模型即服务”(MaaS)的商业模式。董事会认为，战略合作协议为订约方提供宝贵机会利用各自的资源及专业知识，为彼此创造互利及协同效应。因此，董事会认为，签订战略合作协议符合本公司及其股东的整体利益。","news_type":1,"symbols_score_info":{"06887":1.5}},"isVote":1,"tweetType":1,"viewCount":554,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":518493925307488,"gmtCreate":1767614720724,"gmtModify":1767614722918,"author":{"id":"4090276866863740","authorId":"4090276866863740","name":"习惯了__就好","avatar":"https://static.tigerbbs.com/4fa880c152bfa6f9ab5710f93198d571","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4090276866863740","authorIdStr":"4090276866863740"},"themes":[],"title":"","htmlText":"明天大涨","listText":"明天大涨","text":"明天大涨","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/518493925307488","repostId":"2601835998","repostType":2,"repost":{"id":"2601835998","kind":"news","pubTimestamp":1767611765,"share":"https://www.laohu8.com/m/news/2601835998?lang=zh_CN&edition=full","pubTime":"2026-01-05 19:16","market":"hk","language":"zh","title":"东阳光药(06887)：HECN30227已完成国内首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2601835998","media":"智通财经","summary":"智通财经APP讯，东阳光药 发布公告，HECN30227是集团自主研发并拥有全球知识产权的1类新药，可同时消除 cccDNA和intDNA来源的乙肝表面抗原。临床前数据表明，HECN30227具有泛基因型活性，可高效降低HBsAg水平，对核苷类药物耐药株同样保持突出药效，体内外药效亦优于临床竞品。截至目前，HECN30227已完成国内首例受试者入组。临床前重点品种包括：乙肝ASO：除了HECN30227，公司正同步开发“siRNA+ASO+免疫调节剂”三联疗法，通过多靶点协同作用全面抑制HBV和HBsAg。","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/06887\">东阳光药</a>(06887)发布公告，HECN30227是集团自主研发并拥有全球知识产权的1类新药，可同时消除 cccDNA和intDNA来源的乙肝表面抗原(HBsAg)。临床前数据表明，HECN30227具有泛基因型活性，可高效降低HBsAg水平，对核苷类药物耐药株同样保持突出药效，体内外药效亦优于临床竞品。HECN30227采用集团独特设计的HEC GalNova(N-乙酰半乳糖胺)肝靶向递送系统，在实现精准高效肝脏递送的同时大幅降低脱靶风险。截至目前，HECN30227已完成国内首例受试者入组。</p><p>HECN30227与公司自研的免疫调节剂HEC191834临床前联合用药的重要研究成果，入选2025年美国肝脏疾病研究学会年会(AASLD)“Poster of Distinction”，该称号仅授予评分位列前10%的成果，标志着国际权威学术机构对HECN30227联用组合临床开发潜力的高度认可。</p><p>集团自2022年起进军小核酸领域，构建了“靶点发现-序列设计与合成-化学修饰-递送技术-生物学评价”的全链条研发平台，研发实力已跃居国内第一梯队。依托这一完善的技术平台，公司已申请专利超过50篇，布局超10款小核酸管线，涵盖抗感染、心血管-肾脏-代谢、呼吸系统与肿瘤四大领域，计划未来将保持每年推动多款小核酸药物进入临床阶段，持续巩固自身在小核酸治疗领域的技术领先优势。</p><p>临床前重点品种包括：乙肝ASO：除了HECN30227，公司正同步开发“siRNA+ASO+免疫调节剂”三联疗法，通过多靶点协同作用全面抑制HBV和HBsAg。其中HEC ASO与竞品相比临床前体内外药效更优。双靶点系列：通过“一药双靶”设计，同时沉默两个致病基因或同一基因的多个区域，为复杂疾病提供联合干预的高效解决方案，针对高血脂、高血脂高血压的系列双靶点管线，目前多个分子在大动物模型上显示出强效持久的活性。此外，针对MASH等适应症的双靶点管线正稳步推进中，未来将陆续推进至临床阶段。 脂肪靶向、肺部靶向、抗体递送(AOC)：针对脂肪组织高表达的ALK7靶点，公司自主设计的递送载体在小鼠的脂肪组织对ALK7敲降活性显著于阳性对照，且多个ALK7体外序列活性优于阳性对照。此外，用于治疗肺纤维化的双靶点管线(肺部靶向)、用于治疗癌症的AOC管线正稳步推进中，未来将陆续推进至临床阶段。</p><p>从乙肝siRNA疗法HECN30227开展I期临床到双靶点、脂肪靶向、肺部靶向、AOC 等丰富布局，集团正以“技术+管线+产业化”的立体化布局引领中国小核酸药物创新浪潮。未来，集团将持续加码小核酸技术平台建设，加速攻克未满足的临床需求，为患者带来全球领先的“中国智造”治疗方案。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>东阳光药(06887)：HECN30227已完成国内首例受试者入组</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n东阳光药(06887)：HECN30227已完成国内首例受试者入组\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-05 19:16 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1388791.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，东阳光药(06887)发布公告，HECN30227是集团自主研发并拥有全球知识产权的1类新药，可同时消除 cccDNA和intDNA来源的乙肝表面抗原(HBsAg)。临床前数据表明，HECN30227具有泛基因型活性，可高效降低HBsAg水平，对核苷类药物耐药株同样保持突出药效，体内外药效亦优于临床竞品。HECN30227采用集团独特设计的HEC GalNova(N-乙酰半乳糖胺...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1388791.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1191":"制药","06887":"东阳光药"},"source_url":"http://www.zhitongcaijing.com/content/detail/1388791.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2601835998","content_text":"智通财经APP讯，东阳光药(06887)发布公告，HECN30227是集团自主研发并拥有全球知识产权的1类新药，可同时消除 cccDNA和intDNA来源的乙肝表面抗原(HBsAg)。临床前数据表明，HECN30227具有泛基因型活性，可高效降低HBsAg水平，对核苷类药物耐药株同样保持突出药效，体内外药效亦优于临床竞品。HECN30227采用集团独特设计的HEC GalNova(N-乙酰半乳糖胺)肝靶向递送系统，在实现精准高效肝脏递送的同时大幅降低脱靶风险。截至目前，HECN30227已完成国内首例受试者入组。HECN30227与公司自研的免疫调节剂HEC191834临床前联合用药的重要研究成果，入选2025年美国肝脏疾病研究学会年会(AASLD)“Poster of Distinction”，该称号仅授予评分位列前10%的成果，标志着国际权威学术机构对HECN30227联用组合临床开发潜力的高度认可。集团自2022年起进军小核酸领域，构建了“靶点发现-序列设计与合成-化学修饰-递送技术-生物学评价”的全链条研发平台，研发实力已跃居国内第一梯队。依托这一完善的技术平台，公司已申请专利超过50篇，布局超10款小核酸管线，涵盖抗感染、心血管-肾脏-代谢、呼吸系统与肿瘤四大领域，计划未来将保持每年推动多款小核酸药物进入临床阶段，持续巩固自身在小核酸治疗领域的技术领先优势。临床前重点品种包括：乙肝ASO：除了HECN30227，公司正同步开发“siRNA+ASO+免疫调节剂”三联疗法，通过多靶点协同作用全面抑制HBV和HBsAg。其中HEC ASO与竞品相比临床前体内外药效更优。双靶点系列：通过“一药双靶”设计，同时沉默两个致病基因或同一基因的多个区域，为复杂疾病提供联合干预的高效解决方案，针对高血脂、高血脂高血压的系列双靶点管线，目前多个分子在大动物模型上显示出强效持久的活性。此外，针对MASH等适应症的双靶点管线正稳步推进中，未来将陆续推进至临床阶段。 脂肪靶向、肺部靶向、抗体递送(AOC)：针对脂肪组织高表达的ALK7靶点，公司自主设计的递送载体在小鼠的脂肪组织对ALK7敲降活性显著于阳性对照，且多个ALK7体外序列活性优于阳性对照。此外，用于治疗肺纤维化的双靶点管线(肺部靶向)、用于治疗癌症的AOC管线正稳步推进中，未来将陆续推进至临床阶段。从乙肝siRNA疗法HECN30227开展I期临床到双靶点、脂肪靶向、肺部靶向、AOC 等丰富布局，集团正以“技术+管线+产业化”的立体化布局引领中国小核酸药物创新浪潮。未来，集团将持续加码小核酸技术平台建设，加速攻克未满足的临床需求，为患者带来全球领先的“中国智造”治疗方案。","news_type":1,"symbols_score_info":{"06887":1.5}},"isVote":1,"tweetType":1,"viewCount":585,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":481753468425088,"gmtCreate":1758639596512,"gmtModify":1758640713515,"author":{"id":"4090276866863740","authorId":"4090276866863740","name":"习惯了__就好","avatar":"https://static.tigerbbs.com/4fa880c152bfa6f9ab5710f93198d571","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4090276866863740","authorIdStr":"4090276866863740"},"themes":[],"title":"","htmlText":"200手中一签","listText":"200手中一签","text":"200手中一签","images":[{"img":"https://static.tigerbbs.com/0f475a1bea19f70cd05f78495f251436","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/481753468425088","isVote":1,"tweetType":1,"viewCount":481,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":470180818288696,"gmtCreate":1755761609110,"gmtModify":1755763590848,"author":{"id":"4090276866863740","authorId":"4090276866863740","name":"习惯了__就好","avatar":"https://static.tigerbbs.com/4fa880c152bfa6f9ab5710f93198d571","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4090276866863740","authorIdStr":"4090276866863740"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/06887\">$东阳光药(06887)$ </a> 狗托些出来走两圈","listText":"<a href=\"https://laohu8.com/S/06887\">$东阳光药(06887)$ </a> 狗托些出来走两圈","text":"$东阳光药(06887)$ 狗托些出来走两圈","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/470180818288696","isVote":1,"tweetType":1,"viewCount":1112,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":459603190625120,"gmtCreate":1753245118680,"gmtModify":1753246158375,"author":{"id":"4090276866863740","authorId":"4090276866863740","name":"习惯了__就好","avatar":"https://static.tigerbbs.com/4fa880c152bfa6f9ab5710f93198d571","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4090276866863740","authorIdStr":"4090276866863740"},"themes":[],"title":"","htmlText":"75","listText":"75","text":"75","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/459603190625120","isVote":1,"tweetType":1,"viewCount":887,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":425544846680264,"gmtCreate":1744902897154,"gmtModify":1744902915823,"author":{"id":"4090276866863740","authorId":"4090276866863740","name":"习惯了__就好","avatar":"https://static.tigerbbs.com/4fa880c152bfa6f9ab5710f93198d571","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4090276866863740","authorIdStr":"4090276866863740"},"themes":[],"title":"","htmlText":"哈哈哈","listText":"哈哈哈","text":"哈哈哈","images":[{"img":"https://static.tigerbbs.com/86d727a6fb9b2187825f4d96106f94fa","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/425544846680264","isVote":1,"tweetType":1,"viewCount":1164,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0}],"lives":[]}